161 related articles for article (PubMed ID: 11738472)
1. Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG)(n)/Q(n)-expansion diseases?
Cooper AJ; Jeitner TM; Gentile V; Blass JP
Neurochem Int; 2002 Jan; 40(1):53-67. PubMed ID: 11738472
[TBL] [Abstract][Full Text] [Related]
2. Lysine-rich histone (H1) is a lysyl substrate of tissue transglutaminase: possible involvement of transglutaminase in the formation of nuclear aggregates in (CAG)(n)/Q(n) expansion diseases.
Cooper AJ; Wang J; Pasternack R; Fuchsbauer HL; Sheu RK; Blass JP
Dev Neurosci; 2000; 22(5-6):404-17. PubMed ID: 11111157
[TBL] [Abstract][Full Text] [Related]
3. Structural characterization of transglutaminase-catalyzed cross-linking between glyceraldehyde 3-phosphate dehydrogenase and polyglutamine repeats.
Ruoppolo M; Orrù S; Francese S; Caputo I; Esposito C
Protein Sci; 2003 Jan; 12(1):170-9. PubMed ID: 12493840
[TBL] [Abstract][Full Text] [Related]
4. Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases.
Gentile V; Sepe C; Calvani M; Melone MA; Cotrufo R; Cooper AJ; Blass JP; Peluso G
Arch Biochem Biophys; 1998 Apr; 352(2):314-21. PubMed ID: 9587422
[TBL] [Abstract][Full Text] [Related]
5. Polyglutamine domains are substrates of tissue transglutaminase: does transglutaminase play a role in expanded CAG/poly-Q neurodegenerative diseases?
Cooper AJ; Sheu KF; Burke JR; Onodera O; Strittmatter WJ; Roses AD; Blass JP
J Neurochem; 1997 Jul; 69(1):431-4. PubMed ID: 9202340
[TBL] [Abstract][Full Text] [Related]
6. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei.
Karpuj MV; Garren H; Slunt H; Price DL; Gusella J; Becher MW; Steinman L
Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7388-93. PubMed ID: 10377424
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability.
Cooper AJ; Sheu KF; Burke JR; Strittmatter WJ; Gentile V; Peluso G; Blass JP
J Neurochem; 1999 Mar; 72(3):889-99. PubMed ID: 10037459
[TBL] [Abstract][Full Text] [Related]
8. Transglutaminase-catalyzed reactions responsible for the pathogenesis of celiac disease and neurodegenerative diseases: from basic biochemistry to clinic.
Martin A; Romito G; Pepe I; De Vivo G; Merola MR; Limatola A; Gentile V
Curr Med Chem; 2006; 13(16):1895-902. PubMed ID: 16842200
[TBL] [Abstract][Full Text] [Related]
9. Calmodulin regulates transglutaminase 2 cross-linking of huntingtin.
Zainelli GM; Ross CA; Troncoso JC; Fitzgerald JK; Muma NA
J Neurosci; 2004 Feb; 24(8):1954-61. PubMed ID: 14985437
[TBL] [Abstract][Full Text] [Related]
10. Does tissue transglutaminase play a role in Huntington's disease?
Lesort M; Chun W; Tucholski J; Johnson GV
Neurochem Int; 2002 Jan; 40(1):37-52. PubMed ID: 11738471
[TBL] [Abstract][Full Text] [Related]
11. Transglutaminase activity is related to CAG repeat length in patients with Huntington's disease.
Cariello L; de Cristofaro T; Zanetti L; Cuomo T; Di Maio L; Campanella G; Rinaldi S; Zanetti P; Di Lauro R; Varrone S
Hum Genet; 1996 Dec; 98(6):633-5. PubMed ID: 8931689
[TBL] [Abstract][Full Text] [Related]
12. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.
Jana NR; Zemskov EA; Wang Gh ; Nukina N
Hum Mol Genet; 2001 May; 10(10):1049-59. PubMed ID: 11331615
[TBL] [Abstract][Full Text] [Related]
13. Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications.
Karpuj MV; Becher MW; Steinman L
Neurochem Int; 2002 Jan; 40(1):31-6. PubMed ID: 11738470
[TBL] [Abstract][Full Text] [Related]
14. Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration.
Citron BA; Suo Z; SantaCruz K; Davies PJ; Qin F; Festoff BW
Neurochem Int; 2002 Jan; 40(1):69-78. PubMed ID: 11738473
[TBL] [Abstract][Full Text] [Related]
15. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells.
Chun W; Lesort M; Tucholski J; Faber PW; MacDonald ME; Ross CA; Johnson GV
Neurobiol Dis; 2001 Jun; 8(3):391-404. PubMed ID: 11442349
[TBL] [Abstract][Full Text] [Related]
16. Transglutaminase cross-links in intranuclear inclusions in Huntington disease.
Zainelli GM; Ross CA; Troncoso JC; Muma NA
J Neuropathol Exp Neurol; 2003 Jan; 62(1):14-24. PubMed ID: 12528814
[TBL] [Abstract][Full Text] [Related]
17. [Transglutaminase and neurodegenerative diseases].
Liu Z; Zeng J; Zeng S; Tang B; Wang J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Aug; 32(4):562-6. PubMed ID: 26252108
[TBL] [Abstract][Full Text] [Related]
18. Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system.
Kahlem P; Terré C; Green H; Djian P
Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14580-5. PubMed ID: 8962095
[TBL] [Abstract][Full Text] [Related]
19. Role of the transglutaminase enzymes in the nervous system and their possible involvement in neurodegenerative diseases.
De Vivo G; Di Lorenzo R; Ricotta M; Gentile V
Curr Med Chem; 2009; 16(36):4767-73. PubMed ID: 19929789
[TBL] [Abstract][Full Text] [Related]
20. Transglutaminase-catalyzed post-translational modifications of proteins in the nervous system and their possible involvement in neurodegenerative diseases.
De Vivo G; Gentile V
CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):370-5. PubMed ID: 18991665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
